

Colombia Médica colombiamedica.univalle.edu.co

Original Article

Cancer incidence and mortality in the municipality of Pasto, 1998 - 2007

Incidencia y mortalidad por cáncer en el municipio de Pasto 1998 - 2007

María Clara Yépez^{a*}, Luis Eduardo Bravo^b, Arsenio Hidalgo Troya^c, Daniel Marcelo Jurado^a, Luisa Mercedes Bravo^a.

^aCentro de Estudios en Salud, Universidad de Nariño, Cancer Registry of Pasto.

^b Departament of Pathology, Universidad del Valle, Colombia.

^c Cancer Registry of Pasto, Departament of Mathematics, Universidad de Nariño.

Yépez MC, Bravo LE, Hidalgo TA, Jurado DM, Bravo LM. Cancer incidence and mortality in the municipality of Pasto 1998 - 2007. Colomb. Med. 2012; 43(4) 256-66

© 2012 Universidad del Valle. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article history:

Received 2 April 2012 Received in revised form 20 May 2012 Accepted 2 October 2012 Available online 30 December 2012

Keywords:

Incidence, mortality, cancer, prevention, *Helicobacter pylori*, human papillomavirus.

Palabras clave:

Incidencia; mortalidad; cáncer; prevención; *Helicobacter pylori*; Virus del papiloma humano

Abstract

Introduction: In Colombia, information on cancer morbidity at the population level is limited. Incidence estimates for most regions are based on mortality data. To improve the validity of these estimates, it is necessary that other population-based cancer registries, as well as Cali, provide cancer risk information. **Objective:** To describe the incidence and cancer mortality in the municipality of Pasto within the 1998-2007 period.

Methods: The study population belongs to rural and urban areas of the municipality of Pasto. Collection, processing, and systematization of the data were performed according to internationally standardized parameters for population-based cancer registries. The cancer incidence and mortality rates were calculated by gender, age, and tumor site.

Results: During the 1998-2007 period 4,986 new cases of cancer were recorded of which 57.7% were in female. 2,503 deaths were presented, 52% in female. Neoplasm-associated infections are the leading cause of cancer morbidity in Pasto: stomach cancer in males and cervical cancer in females.

Discussion: Cancer in general is a major health problem for the population of the municipality of Pasto. The overall behavior of the increasing incidence and cancer mortality in relation to other causes of death show the need to implement and strengthen prevention and promotion programs, focusing especially on tumors that produce greater morbidity and mortality in the population.

Resumen

Introducción. En Colombia es limitada la información de morbilidad por cáncer dentro de la población. Las estimaciones de incidencia para la mayoría de las regiones se basan en los datos de mortalidad. Para mejorar la validez de estas estimaciones, es necesario que otros Registros poblacionales de cáncer, además de Cali, proporcionen información del riesgo de cáncer.

Objetivo. Describir la incidencia y mortalidad por cáncer en el municipio de Pasto durante el período 1998-2007.

Métodos. La población objeto de estudio pertenece al área rural y urbana del municipio de Pasto. La recolección, procesamiento y sistematización de los datos se realizó de acuerdo con parámetros estandarizados internacionalmente para Registros poblacionales de cáncer. Las tasas de incidencia y mortalidad se calcularon por género, edad y localización del tumor.

Resultados. En el período 1998-2007 se registraron 4.986 casos nuevos de cáncer, de ellos, 57.7% se presentó en mujeres. Se reportaron 2,503 muertes, 52% en mujeres. Las neoplasias asociadas con infecciones son la primera causa de morbilidad por cáncer en Pasto: cáncer de estómago en hombres y cáncer de cuello uterino en mujeres.

Discusión. El cáncer, en general, constituye un importante problema de salud para la población del municipio de Pasto. El comportamiento global de la incidencia y el aumento de la mortalidad por cáncer en relación con otras causas de muerte, evidencian la necesidad de fomentar y fortalecer programas de promoción y prevención, enfocados especialmente hacia los tumores que producen mayor morbi-mortalidad en la población.

*Corresponding author:

E-mail address: macych@gmail.com (Yépez MC), bravoluiseduardo@gmail. com(Bravo LE), arsenio.hidalgo@gmail.com (Hidalgo A), danieljuradof@gmail. com (Jurado DM), lume.goyes@gmail.com (Bravo LM)

Introduction

Cancer is one of the main causes of morbidity and mortality in the world; for 2008 a total of 12,662,600 new cases were estimated of which 52% occurred in males. It is considered that cancer is responsible for 13% of the world's deaths. By 2030, the World Health Organization (WHO) expects significant growth in the magnitude of this important public health problem, as a product of the population's demographic growth and aging. It is estimated that the new cases will rise to 21-million and mortality due to cancer will increase to 45%, causing approximately 13-million deaths. The first causes of morbidity and mortality due to cancer in the world are lung, breast, colorectal, stomach, liver, and prostate cancer^{1, 2}.

In Colombia, information on cancer is still limited at the population level and estimations of incidence are obtained based on mortality data³. For the 2002 – 2006 period, 70,000 cases were estimated, with incidence rates per 100,000 person-years, age-adjusted to the world standard population, of 186.6 in males and 196.9 in females. The most frequent site of cancer in males were prostate, stomach, and lung; in females, breast, cervix, and thyroid. The departments with the highest incidence were: Risaralda, Caldas, Antioquia, Valle del Cauca, and Quindío⁴.

To address this problem, the Ministry of Health and Colombia's National Cancer Institute (NCI) launched the Plan for Cancer Control, seeking to set into motion actions by the state, inter-sector actions, business social responsibility, and individual responsibility to provide cancer control and position cancer within the nation's public agenda as a public health problem in Colombia. To execute this plan, it is initially fundamental to describe the epidemiological situation of cancer within the population and evaluate the determinant factors, thus, permitting the healthcare system to guide the oncology services and present an adequate social response.

The Cancer Registry of Pasto (RPCMP, for the term in Spanish) has been continually operating since 1998 and its mission is that of providing quality and reliable information on cancer in the Municipality; thereby, facilitating the implementation of intervention programs aimed at diminishing the burden of this disease in the region. Currently, it is part of the International Association of Cancer Registries (IACR) and the Network of Population-based Cancer Registries of Colombia, along with the Registries in Cali, Bucaramanga, Manizales, and Barranquilla.


This study describes cancer incidence and mortality in the municipality of Pasto during the 1998-2002 and 2003-2007 periods, as the contribution made by the RPCMP to the knowledge of cancer behavior in the Municipality and the contribution to achieving the objective goals of the National Plan National for Cancer Control.

Materials and Methods

The study was carried out under a descriptive epidemiological design on cancer in the urban and rural population of the municipality of Pasto, in the Department of Nariño. The population reported for this municipality by Colombia's National Administrative Department on Statistics (Departamento Administrativo Nacional de Estadísticas - DANE) through the last official census of 2005, was 382,422 inhabitants; 81.7% living in the urban zone (Fig. 1).

The study included all malignant tumors diagnosed in individuals residing in the municipality of Pasto during the 1998-2007 period. Additionally, tumors of uncertain nature, benign tumors of the central nervous system (SNC), and tumors *in situ* were also included. Date of incidence corresponds to the first chronological event of diagnostic confirmation of the disease or, in case of

Figure 1. Municipality of Pasto, Colombia. Population structure by sex and 5-year age groups. 2005 General census. Source: Departamento Administrativo Nacional de Estadísticas (DANE). Census population



the lack of data, date of death was used. The information was gathered in active, continuous, and systematic manner in the healthcare institutions that generate information on cancer: hospitals, clinics, oncology units, pathology and hematology laboratories, medical centers, specialized clinics, the Municipal Secretary of Health, which is the organism in charge of processing the municipality's death certificates, and DANE, which provides the official mortality base. The data gathered are related to the patient's socio-demographic variables, clinical aspects of the tumor, and follow up. Information collected was worked on according to confidentiality criteria imposed by the International Agency for Cancer on Research (IACR) for Populationbased Cancer Registries.

The cases were entered into the system to eliminate duplicates, processing and complementing data. Identification of multiple primary tumors followed IARC standards⁵. The topography (sites) and morphology (histology) of the tumors were coded with the International Classification of Diseases for Oncology Third edition (ICD-O-3). For comparative purposes, the conversion of the sites coding was made to ICD-10 (International Classification of Diseases 10th edition) and some sites were grouped. To validate the internal consistency among variables, an automatic check was made with the IARCcrg Tools program version 2.05 and rare cases were resolved in a scientific committee conformed by specialists.

For the 1998-2007 period, the percentage of cases

Table 1. Municipality of Pasto, Colombia. Quality indices, 10 firstincidents tumors. Men and women, 1998-2007

	Mal	е								
Site	n	%MV	%DCO	%Others						
Stomach	548	80.1	13.9	6						
Prostate	363	79.6	11	9.4						
Lymphomas	156	94.2	2.6	3.2						
Lung	106	55.7	25.5	18.9						
Colon and rectum	98	83.7	8.2	8.2						
Unknown primary site	2110	78.3	11.5	10.1						
Female										
site	n	%MV	%DCO	%Others						
Cervix uteri	534	91.9	2.4	5.6						
Breast	474	93.9	3.8	2.3						
Stomach	350	74.6	6.6	18.9						
Thyroid	158	94.3	3.8	1.9						
Colon and rectum	136	77.2	11	11.8						
Unknown primary site	2876	82.9	10.2	7						

diagnosed through microscopic verification (histology of primary tumor, cytology, and bone marrow aspirate) in males was 78.3% and 91.9% in female; the percentage of cases registered as death certificate only was 11.5% in males and 10.2% in females. Other diagnostic methods included: imaging, exploratory surgery, clinical impressions, and endoscopy. The percentage distribution of indices of data quality for the first ten sites is shown in Table 1. The percentage of deaths with age unknown was 0.3% and the percentage of deaths with unknown primary site (C76-C80) was 5%.

Incidence rates and mortality were conventionally calculated by using as denominator the population estimations and projections by midyear calculated from the 2005 official census⁶. Cases without age, basal cell and squamous cell carcinomas of the skin, and tumors in situ were excluded. Age-standardised rates were estimated via the direct method with the world standard population, specific rates were calculated via the following variables: gender, sites, and age according to quinquennial ranges (18 categories) and large groupings. Cancer incidence and mortality results are presented for the 1998-2002 and 2003-2007 periods in specific tables or figures and in-depth analysis was performed of the main sites, given that these are diseases of great relevance for the region. To observe the cancer incidence and mortality increase or decrease between both study periods, the rate percentage change was assessed.

Results

Global cancer incidence and mortality per 100,000 person-years.

During the 1998-2007 period, 4.986 new cancer cases were registered in the municipality of Pasto, of them 57.7% occurred in females. A total of 45.5% of the cases occurred in individuals older than 65 years of age; 2% of the cases were observed in individuals younger than 15 years of age. The mean age upon diagnosis was 62 years of age in males and 57 years of age in females. During the same period, 2,503 deaths occurred due to cancer, 52% occurred in females. The greatest proportion of deaths happened as of 65 years of age, both in males (62%) as in females (53%). The mean age of death for males was estimated at 66 years and 64 years for females.

Table 2. Municipality of Pasto, Colombia. Incidence rates of cancer, crude and age-standardized (world population) per 100,000person-years in men by location, 1998-2002 and 2003-2007

Oral Cavity and Pharynx 15 1.5 1.8 2.3 12 1.1 1.3 1.6 [0.28] [0.3] C Oesophagus 36 3.7 4.2 4.8 2.3 2 2.5 3 [0.4] -0.38 C Stomach 298 30.5 35 42.6 250 22.1 27.3 31.7 [0.2] [0.24] 0.2 0.2 0.3 1.2 C C C C Colon and rectum 42 4.3 4.9 5.9 5.6 4.9 6.1 7.3 0.24		1998 2002						2003	3 2007	APC	: (%)	
Oesophagus 36 3.7 4.2 4.8 23 2 2.5 3 [0.4] -0.38 C Stomach 298 30.5 35 42.6 250 22.1 27.3 31.7 [0.2] [0.26] C Small intestine 4 0.4 0.5 0.6 5 0.4 0.5 0.6 C C Colon and rectum 42 4.3 4.9 5.9 5.6 4.9 6.1 7.3 0.24 0.24 0.2 0.2 0.3 1 2.0 C 1.0 1 0.1 0.1 2.2 2.0 2.0 0.3 1 0.5 C D D D 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 D D D D D D D D D D D D D D D D <td< th=""><th>Site</th><th>n</th><th>(%)</th><th>CR</th><th>ASR</th><th>n</th><th>(%)</th><th>CR</th><th>ASR</th><th>CR</th><th>ASR</th><th>Code ICD 10</th></td<>	Site	n	(%)	CR	ASR	n	(%)	CR	ASR	CR	ASR	Code ICD 10
shomach 298 30.5 35 42.6 250 22.1 27.3 31.7 [0.22] [0.24] C Small Intestine 4 0.4 0.5 0.6 5 0.4 0.5 0.6 C C Colon and rectum 42 4.3 4.9 5.9 56 4.9 0.2 0.2 0.2 0.2 0.3 1 2.0 Liver 26 2.7 3.5 3.8 28 2.5 3.6 3.7 0.03 [0.03] C Gallbladder 17 1.7 2 2.4 35 3.1 3.8 4.3 0.9 0.79 C La 1.43 1.56 C Larynx 6 0.6 0.7 0.9 16 1.4 1.7 2.3 1.43 1.56 C Connective sinues etc 1 0.1 0.1 0.2 2 0.2 0.2 0.1 0.5 C Connective tissue 1 1.1 1.4 1.6 1.7 3.5 3.9 1.19<	Oral Cavity and Pharynx		1.5	1.8	2.3	12	1.1		1.6	[0.28]	[0.3]	C00 14
Small intestine 4 0.4 0.5 0.6 5 0.4 0.5 0.6 0.4 0.2 0.3 1 C C Colon and rectum 42 4.3 4.9 5.9 5.6 4.9 6.1 7.3 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 <td>Oesophagus</td> <td>36</td> <td>3.7</td> <td>4.2</td> <td>4.8</td> <td>23</td> <td>2</td> <td>2.5</td> <td>3</td> <td>[0.4]</td> <td>-0.38</td> <td>C15</td>	Oesophagus	36	3.7	4.2	4.8	23	2	2.5	3	[0.4]	-0.38	C15
Colon and rectum 42 4.3 4.9 5.9 56 4.9 6.1 7.3 0.24 0.24 0.2 Anus 1 0.1 0.1 0.1 2 0.2 0.3 1 2 C Gallbladder 17 1.7 2 2.6 2.6 3.6 3.7 0.03 C Pancreas 17 1.7 2 2.6 3.6 3.8 2.8 2.2 2.7 0.1 0.04 C Pancreas 17 1.7 2 2.4 35 3.1 3.8 4.3 0.9 0.77 C Nose, sinuses etc 1 0.1 0.1 0.2 2 0.2 0.2 0.1 0.6 C Cohenctive tissue 4 4.4 1.6 1.7 32 8.5 3.5 1.1 1.1 1.2 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 0.5 0.7 C C C <t< td=""><td>Stomach</td><td>298</td><td>30.5</td><td>35</td><td>42.6</td><td>250</td><td>22.1</td><td>27.3</td><td>31.7</td><td>[0.22]</td><td>[0.26]</td><td>C16</td></t<>	Stomach	298	30.5	35	42.6	250	22.1	27.3	31.7	[0.22]	[0.26]	C16
Anus 1 0.1 0.1 0.1 2 0.2 0.2 0.3 1 2.0 2 Liver 26 2.7 3.5 3.8 2.5 3.6 3.7 0.03 [0.03] C Collbladder 17 1.7 2 2.4 35 3.8 4.2 2.7 0.1 0.04 C Pancreas 17 1.7 2 2.4 35 3.1 3.8 4.3 0.9 0.97 C Nose, sinuses etc 1 0.1 0.1 0.2 2.2 2.02 0.3 1 0.5C Carpox 6 0.6 0.7 0.9 1.6 1.4 1.7 1.5 1.3 0.6C Connective tissue 48 4.9 5.6 6.8 58 5.1 6.3 7.2 0.1 0.0	Small intestine	4	0.4	0.5	0.6	5	0.4	0.5	0.6			C17
Liver 26 2.7 3.5 3.8 28 2.5 3.6 3.7 0.03 [0.03] C Gallbladder 17 1.7 2 2.6 0 1.8 2.2 2.7 0.1 0.04 C Pancreas 17 1.7 2 2.4 35 3.1 3.8 4.3 0.9 0.79 C Nose. sinuses etc 1 0.1 0.1 0.2 2 0.2 0.2 0.3 1 0.5 C Carynx 6 0.6 0.7 0.9 16 1.4 1.7 2.3 1.43 1.56 C Carynx 6 0.6 0.7 0.9 16 1.4 1.4 1.6 1.6 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.5 1.4 1.4 1.5 1.4 1.7 2.2 0.2 0.2 0.2 0.2 0.2 0.2	Colon and rectum	42	4.3	4.9	5.9	56	4.9	6.1	7.3	0.24	0.24	C18 20
Gallbladder 17 1.7 2 2.6 20 1.8 2.2 2.7 0.1 0.0 C Cancreas 17 1.7 2 2.4 35 3.1 3.8 4.3 0.9 0.79 C Sose, sinuses etc. 1 0.1 0.1 0.2 2.2 0.2 0.2 0.3 1.43 1.56 C Carporacic organs 0 0 0 4 4.4 1.7 2.3 1.43 1.56 C Connective tissue 8 0.8 0.9 0.9 7 0.6 0.8 0.9 [0.11] C C Connective tissue 14 1.4 1.6 1.7 32 2.8 3.5 3.9 1.19 1.29 C Vesothelioma 1 0.1	Anus	1	0.1	0.1	0.1	2	0.2	0.2	0.3	1	2	C21
Pancreas 17 1.7 2 2.4 35 3.1 3.8 4.3 0.9 0.79 C Vase. sinuses etc 1 0.1 0.1 0.2 0.2 0.2 0.3 1 0.5 C carpnx 6 0.6 0.7 0.9 16 1.4 1.7 2.3 1.43 1.56 C Crachea. bronchus and Lung 48 4.9 5.6 6.8 58 5.1 6.3 7.2 0.13 0.06 C C Connective fissue 14 1.4 1.6 1.7 32 2.8 3.5 3.9 1.19 1.29 C Connective fissue 14 1.4 1.6 1.7 32 2.8 3.5 3.9 1.19 1.29 C Caposi sarcoma 0 0 0 0 1 1.1 1.3 1.6 1.4 1.7 2.5 0.31 0.67 C Caposi sarcoma 0 0 0 0 0 0 2 2.2 2.8 0.11 1 1.2 1.4	iv er	26	2.7	3.5	3.8	28	2.5	3.6	3.7	0.03	[0.03]	C22
Nose. sinuses etc 1 0.1 0.1 0.2 2 0.2 0.3 1 0.5 C arynx 6 0.6 0.7 0.9 16 1.4 1.7 2.3 1.43 1.56 C arynx 0 0 0 0 4 0.4 0.4 0.5 C C Other thoracic organs 0 0 0 0 4 0.4 0.4 0.5 C C Sones 8 0.8 0.9 0 0 4 0.4 0.5 C C Caposisarcoma 1 0.1 0.1 0.2 2 0.2 0.2 1.1 1.2 C Aesothelioma 11 1.1 1.3 1.5 16 1.4 1.7 2.5 0.31 0.67 C Adeposisarcoma 0 0 0 0 1.1 1.1 1.1 1.1 1.1 1.1 1.3 1.6 1.6 0.63 0.78 C C C C C	Gallbladder	17	1.7	2	2.6	20	1.8	2.2	2.7	0.1	0.04	C23 24
arynx 6 0.6 0.7 0.9 16 1.4 1.7 2.3 1.43 1.56 C rachea. bronchus and Lung 48 4.9 5.6 6.8 58 5.1 6.3 7.2 0.13 0.06 C Dther thoracic organs 0 0 0 0 4 0.4 0.4 0.5 C C Connective fissue 14 1.4 1.6 1.7 32 2.8 3.5 3.9 1.19 1.29 C Connective fissue 14 1.4 1.6 1.7 32 2.8 3.5 3.9 1.19 1.29 C Aesothelioma 1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 C C 0.2 0.2 0.2 0.2 0.3 0.67 C	Pancreas	17	1.7	2	2.4	35	3.1	3.8	4.3	0.9	0.79	C25
rachea. bronchus and Lung 48 4.9 5.6 6.8 58 5.1 6.3 7.2 0.13 0.06 C Other thoracic organs 0 0 0 0 4 0.4 0.4 0.4 0.5 C C Connective tissue 14 1.4 1.6 1.7 32 2.8 3.5 3.9 1.19 1.29 C Caposi sarcoma 0 0 0 0 1 0.	lose. sinuses etc	1	0.1	0.1	0.2	2	0.2	0.2	0.3	1	0.5	C30 31
rachea. bronchus and Lung 48 4.9 5.6 6.8 58 5.1 6.3 7.2 0.13 0.06 C Other thoracic organs 0 0 0 0 4 0.4 0.4 0.4 0.5 C C Connective tissue 14 1.4 1.6 1.7 32 2.8 3.5 3.9 1.19 1.29 C Caposi sarcoma 0 0 0 0 1 0.	arynx	6	0.6	0.7		16	1.4			1.43		
Dther thoracic organs 0 0 0 0 4 0.4 0.4 0.5 C Sones 8 0.8 0.9 7 0.6 0.8 0.9 [0.11] C Connective tissue 14 1.4 1.6 1.7 32 2.8 3.5 3.9 1.19 1.29 C Kesothelioma 1 0.1 0.1 0.2 2 0.2 0.2 0.1 C Kesothelioma 1 1.1 1.3 1.6 1.4 1.7 2.5 0.31 0.67 C Ketanoma of skin 11 1.1 1.3 1.6 1.63 0.78 C		48	4.9	5.6	6.8	58	5.1	6.3	7.2	0.13		C33 34
Bones 8 0.8 0.9 0.9 7 0.6 0.8 0.9 [0.11] C Connective tissue 14 1.4 1.6 1.7 32 2.8 3.5 3.9 1.19 1.29 C Aesothelioma 1 0.1 0.1 0.2 2 0.2 0.2 1 C Saposi sarcoma 0 0 0 0 1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 C C Adelanoma of skin 11 1.1 1.3 1.5 1.6 1.4 1.7 2.5 0.31 0.67 C Vereast 7 0.7 0.8 0.1 1 1.1 1.2 1.4 0.5 0.27 C Ce Peristics 0.22 0.2	8		0	0	0	4	0.4	0.4				C37 38
Connective tissue 14 1.4 1.6 1.7 32 2.8 3.5 3.9 1.19 1.29 C Aesothelioma 1 0.1 0.1 0.2 2 0.2 0.2 0.2 1 C Caposisarcoma 0 0 0 0 1 1.1 1.1 1.2 1.4 1.7 2.5 0.31 0.67 C Aelanoma of skin 11 1.1 1.3 1.5 1.6 1.4 1.7 2.5 0.31 0.67 C Venterskin 7 0.7 0.8 0.9 12 1.1 1.3 1.6 0.63 0.78 C Venstate 160 16.4 18.8 22.6 2.03 17.9 22.2 2.8 0.14 C 0.7 0.71 0.8 1.4 1.6 1.7 7 0.7 0.7 0.8 1.4 1.0 0.1 0.1 0.1 0.1 0.7 0.71 0.8 1.4 1.8 1.6 1.7 1.01 0.7 0.24 <t< td=""><td>5</td><td>8</td><td>0.8</td><td></td><td>0.9</td><td></td><td>0.6</td><td></td><td></td><td>[0.11]</td><td></td><td>C40 41</td></t<>	5	8	0.8		0.9		0.6			[0.11]		C40 41
Aesothelioma 1 0.1 0.2 2 0.2 0.2 1 CC Caposi sarcoma 0 0 0 0 1 0.1 <t< td=""><td>Connective tissue</td><td>14</td><td>1.4</td><td>1.6</td><td>1.7</td><td>32</td><td>2.8</td><td>3.5</td><td></td><td></td><td>1.29</td><td>C47.49</td></t<>	Connective tissue	14	1.4	1.6	1.7	32	2.8	3.5			1.29	C47.49
Caposi sarcoma 0 0 0 1 0.1 1.1 11 1.2 1.4 0.5 0.27 C Penis 7 0.7 0.8 1.1 11 1 1.2 1.4 0.5 0.27 C <td><i>A</i>esothelioma</td> <td>1</td> <td>0.1</td> <td>0.1</td> <td>0.2</td> <td></td> <td></td> <td></td> <td></td> <td>1</td> <td></td> <td>C45</td>	<i>A</i> esothelioma	1	0.1	0.1	0.2					1		C45
Arelanoma of skin 11 1.1 1.3 1.5 16 1.4 1.7 2.5 0.31 0.67 C Drher skin 7 0.7 0.8 0.9 12 1.1 1.3 1.6 0.63 0.78 C reast 0 0 0 0 2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	(aposi sarcoma	0	0	0		1						C46
Dther skin 7 0.7 0.8 0.9 12 1.1 1.3 1.6 0.63 0.78 C reast 0 0 0 0 2 0.2 0.2 0.2 0.2 C C renis 7 0.7 0.8 1.1 11 1 1.2 1.4 0.5 0.27 C trostate 160 16.4 18.8 22.6 203 1.79 22.2 25.8 0.18 0.14 C estis 22 2.3 2.6 2.4 42 3.7 4.6 4.1 0.77 0.71 C Other male genital organs 1 0.1 0.1 1.1 1.3 1.6 1.7 [0.19] C Cladder 35 3.6 4.1 4.8 27 2.4 3 3.6 [0.86] C Crain. nerv ous system 25 2.6 2.9 3.1 44 3.9 4.8 5.6 0.66 0.81 C Adrenal gland 11 1.1		11		1.3	1.5	16	1.4	1.7	2.5	0.31	0.67	C43
irreast 0 0 0 0 2 0.2 <td></td> <td>7</td> <td></td>		7										
Penis70.70.81.11111.21.40.50.27CProstate16016.418.822.620317.922.225.80.180.14Cestis222.32.62.4423.74.64.10.770.71COther male genital organs10.10.10.110.10.10.10.10.10.10.10.1Viadder353.64.14.8272.433.6[0.27]-0.25COther urinary organs000010.10.10.10.10.1CVige70.70.81.410.10.10.10.2[0.88][0.86]CVige70.70.81.410.10.10.10.1CCVige70.70.81.410.10.10.1CCVige70.70.81.410.10.10.1CCVige70.70.81.410.10.10.1CCVige70.70.81.4110.10.1CCVige70.70.81.4110.10.1CCVige111.11.31.4181.6 <td></td> <td>C50</td>												C50
Invostate16016.418.822.620317.922.225.80.180.14 Cestis222.32.62.4423.74.64.10.770.71 CDther male genital organs10.10.10.1110.10.10.10.10.1idney141.41.62.1151.31.61.7[0.19] Cladder353.64.14.8272.433.6[0.27]-0.25 CDther urinary organs000010.10.11Cye70.70.81.410.10.10.2[0.88] Ccrain. nerv ous system252.62.93.1443.94.85.60.660.81 Chyroid111.11.31.4181.622.40.540.71 Ccladgkin disease151.51.81.780.70.91Clodgkin disease151.51.81.780.70.910.11 Cymphocytic Leukemia242.52.82.7282.53.63.80.290.41 CAyeloid Leukemia111.11.31.4171.51.92.10.460.5 Ceukemia of unspecified cell type40.40.50.440.40.40.	lenis	7			1.1					0.5	0.27	
estis 22 2.3 2.6 2.4 42 3.7 4.6 4.1 0.77 0.71 C Dther male genital organs 1 0.1 0.1 0.1 1 0.												
1 0.1 0.1 0.1 1 0.1 </td <td></td>												
idney141.41.62.1151.31.61.7[0.19] CJadder353.64.14.8272.433.6[0.27]-0.25 COther urinary organs000010.10.11COye70.70.81.410.10.10.2[0.88][0.86] CArrain. nerv ous system252.62.93.1443.94.85.60.660.81 Chyroid111.11.31.4181.622.40.540.71 CAdrenal gland000010.10.10.1COther endocrine00010.10.11CAdrenal gland000010.10.11COther endocrine000010.10.10.1CAdrenal gland000010.10.11COther endocrine000010.10.11CAddelin Hypeloma575.86.77.3766.78.39.60.240.32CAultiple Myeloma80.80.90.980.70.910.11 <c< td="">CAyeloid Leukemia111.11.31.4171.51.9<td>) ther male aenital organs</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>••••</td><td>C63</td></c<>) ther male aenital organs										••••	C63
Madder 35 3.6 4.1 4.8 27 2.4 3 3.6 [0.27] -0.25 C Other urinary organs 0 0 0 0 1 0.1 0.1 1 C Sye 7 0.7 0.8 1.4 1 0.1 0.2 [0.88] [0.86] C Varian. nerv ous system 25 2.6 2.9 3.1 44 3.9 4.8 5.6 0.66 0.81 C hyroid 11 1.1 1.3 1.4 18 1.6 2 2.4 0.54 0.71 C Adrenal gland 0 0 0 0 1 0.1 0.1 0.1 C Other endocrine 0 0 0 0 1 0.1 0.1 C Addekin lymphoma 57 5.8 6.7 7.3 76 6.7 8.3 9.6 0.24 0.32 C Autiple Myeloma 8 0.8 0.9 0.9 8 0.7 0.9 1 0.11 C ymphocytic Leukem		14									[0,19]	
Other urinary organs 0 0 0 0 1 0.1 0.1 1 1 C ye 7 0.7 0.8 1.4 1 0.1 0.1 0.2 [0.88] [0.86] C rain. nerv ous system 25 2.6 2.9 3.1 44 3.9 4.8 5.6 0.66 0.81 C hyroid 11 1.1 1.3 1.4 18 1.6 2 2.4 0.54 0.71 C vdrenal gland 0 0 0 0 1 0.1 0.1 0.1 0.1 C Other endocrine 0 0 0 0 1 0.1 0.1 1 C Iodgkin disease 15 1.5 1.8 1.7 8 0.7 0.9 1 [0.5] [0.41] C Aultiple Myeloma 8 0.8 0.9 0.9 8 0.7 0.9 1 0.11 C Ayeloid Leukemia 11 1.1 1.3 1.4	,	35								[0.27]		
ye 7 0.7 0.8 1.4 1 0.1 0.2 [0.88] [0.86] C rain. nerv ous system 25 2.6 2.9 3.1 44 3.9 4.8 5.6 0.66 0.81 C hyroid 11 1.1 1.3 1.4 18 1.6 2 2.4 0.54 0.71 C drenal gland 0 0 0 0 1 0.1 0.1 0.1 0.1 C Other endocrine 0 0 0 0 1 0.1 0.1 1 C Iodgkin disease 15 1.5 1.8 1.7 8 0.7 0.9 1 [0.5] [0.41] C Ion Hodgkin lymphoma 57 5.8 6.7 7.3 76 6.7 8.3 9.6 0.24 0.32 C Aultiple Myeloma 8 0.8 0.9 0.9 8 0.7 0.9 1 0.11 C ymphocytic Leukemia 11 1.1 1.3 1.4										[012/]	0.20	C68
Image: System 25 2.6 2.9 3.1 44 3.9 4.8 5.6 0.66 0.81 C hyroid 11 1.1 1.3 1.4 18 1.6 2 2.4 0.54 0.71 C Adrenal gland 0 0 0 0 1 0.1 0.1 0.1 0.1 C Other endocrine 0 0 0 0 1 0.1 0.1 1 C Hodgkin disease 15 1.5 1.8 1.7 8 0.7 0.9 1 [0.5] [0.41] C Aultiple Myeloma 57 5.8 6.7 7.3 76 6.7 8.3 9.6 0.24 0.32 C Aultiple Myeloma 8 0.8 0.9 0.9 8 0.7 0.9 1 0.11 C Ayeloid Leukemia 11 1.1 1.3 1.4 17 1.5 1.9 2.1 0.46 0.5 C Ayeloid Leukemia 11 1.1 1.3 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>0.2</td> <td>[0 88]</td> <td>[0.86]</td> <td></td>									0.2	[0 88]	[0.86]	
hyroid111.11.31.4181.622.40.540.71CAdrenal gland000010.10.10.10.1COther endocrine000010.10.10.10.1CIodgkin disease151.51.81.780.70.91[0.5][0.41]CIon Hodgkin lymphoma575.86.77.3766.78.39.60.240.32CAultiple Myeloma80.80.90.980.70.910.11Cymphocytic Leukemia242.52.82.7282.53.63.80.290.41CAyeloid Leukemia111.11.31.4171.51.92.10.460.5CAyelodysplastic syndromes000020.20.3CInknown primary site242.52.83.2423.74.650.640.56C												
Adrenal gland000010.10.10.10.1COther endocrine000010.10.111CHodgkin disease151.51.81.780.70.91[0.5][0.41]CNon Hodgkin lymphoma575.86.77.3766.78.39.60.240.32CMultiple Myeloma80.80.90.980.70.910.11CNymphocytic Leukemia242.52.82.7282.53.63.80.290.41CAyeloid Leukemia111.11.31.4171.51.92.10.460.5CAyelodysplastic syndromes000020.20.20.3CJinknown primary site242.52.83.2423.74.650.640.56C												
Dther endocrine 0 0 0 0 1 0.1 0.1 1 1 C Hodgkin disease 15 1.5 1.8 1.7 8 0.7 0.9 1 [0.5] [0.41] C Non Hodgkin lymphoma 57 5.8 6.7 7.3 76 6.7 8.3 9.6 0.24 0.32 C Aultiple Myeloma 8 0.8 0.9 0.9 8 0.7 0.9 1 0.11 C ymphocytic Leukemia 24 2.5 2.8 2.7 28 2.5 3.6 3.8 0.29 0.41 C Ayeloid Leukemia 11 1.1 1.3 1.4 17 1.5 1.9 2.1 0.46 0.5 C Ayelodysplastic syndromes 0 0 0 0 2 0.2 0.2 0.3 C Inknown primary site 24 2.5 2.8 3.2 42 3.7 4.6 5 0.64 0.56 C	,									0.01	0.7 1	C74
Hodgkin disease151.51.81.780.70.91[0.5][0.41]CNon Hodgkin lymphoma575.86.77.3766.78.39.60.240.32CAultiple Myeloma80.80.90.980.70.910.11Cymphocytic Leukemia242.52.82.7282.53.63.80.290.41CAyeloid Leukemia111.11.31.4171.51.92.10.460.5Ceukemia of unspecified cell type40.40.50.440.40.40.5[0.2]0.25CAyelodysplastic syndromes000020.20.3CInknown primary site242.52.83.2423.74.650.640.56C	8											C75
Non Hodgkin lymphoma 57 5.8 6.7 7.3 76 6.7 8.3 9.6 0.24 0.32 C Aultiple Myeloma 8 0.8 0.9 0.9 8 0.7 0.9 1 0.11 C Ayymphocytic Leukemia 24 2.5 2.8 2.7 28 2.5 3.6 3.8 0.29 0.41 C Ayyeloid Leukemia 11 1.1 1.3 1.4 17 1.5 1.9 2.1 0.46 0.5 C Ayeloid Leukemia 11 1.1 1.3 1.4 17 1.5 1.9 2.1 0.46 0.5 C Ayeloidysplastic syndromes 0 0 0 0 2 0.2 0.3 C Jnknown primary site 24 2.5 2.8 3.2 42 3.7 4.6 5 0.64 0.56 C										[0.5]	[0,411	
Multiple Myeloma 8 0.8 0.9 0.9 8 0.7 0.9 1 0.11 C Lymphocytic Leukemia 24 2.5 2.8 2.7 28 2.5 3.6 3.8 0.29 0.41 C Myeloid Leukemia 11 1.1 1.3 1.4 17 1.5 1.9 2.1 0.46 0.5 C Leukemia of unspecified cell type 4 0.4 0.5 0.4 4 0.4 0.5 [0.2] 0.25 C Myelodysplastic syndromes 0 0 0 2 0.2 0.3 C Jnknown primary site 24 2.5 2.8 3.2 42 3.7 4.6 5 0.64 0.56 C	0											C82 85.96
ymphocytic Leukemia242.52.82.7282.53.63.80.290.41CAyeloid Leukemia111.11.31.4171.51.92.10.460.5Ceukemia of unspecified cell type40.40.50.440.40.40.5[0.2]0.25CAyelodysplastic syndromes000020.20.20.3CInknown primary site242.52.83.2423.74.650.640.56C	0 / 1									0.24		
Ayeloid Leukemia 11 1.1 1.3 1.4 17 1.5 1.9 2.1 0.46 0.5 C eukemia of unspecified cell type 4 0.4 0.5 0.4 4 0.4 0.5 [0.2] 0.25 C Ayelodysplastic syndromes 0 0 0 0 2 0.2 0.2 0.3 C Inknown primary site 24 2.5 2.8 3.2 42 3.7 4.6 5 0.64 0.56 C										0.29		
velocities40.40.50.440.40.5[0.2]0.25 CAyelodysplastic syndromes000020.20.20.3CInknown primary site242.52.83.2423.74.650.640.56 C												C92 94
Ayelodysplastic syndromes000020.20.3CJnknown primary site242.52.83.2423.74.650.640.56C												
Inknown primary site 24 2.5 2.8 3.2 42 3.7 4.6 5 0.64 0.56 C										[0.2]	0.20	CIE O 3: 998_/
										0 44	0 54	C1L 0 3. 776_7 C26.39.48.76.8
Nisites 977 100 114.7 134.6 1133 100 123.8 141.6 0.08 0.05 C												C28.37.40.78.0 C00 96
												C00 43.45 96

Number of cases (n); Relative Frequencies (%); Crude Rate (CR); Age-Standardized Incidence Rate (ASR); Annual Percent Change (APC).

The number of new cases for the 2003-2007 period (2,640) increased with respect to the number of cases for the 1998-2002 period (2,346). The global rate percentage change of cancer incidence in males was at 5% and 1% in females. The risk of developing cancer was higher in females with a male/female gender ratio (GRm/w) of 0.9/1 during both periods. Tables 2 and 3 describe the number of cancer cases and incidence rates according to gender and sites of the tumor for both periods evaluated.

In the municipality of Pasto, during 1998-2002, cancer

was the third cause of death after mortality due to cardiovascular disease and deaths due to external causes. During this period, of a total of 7,784 deaths due to all causes, 1,154 died due to cancer (15%). From 2003 to 2007, this value increased to 1,349 deaths that represented 18% of a total of 7,565 deaths; during this period, cancer became the second cause of mortality in the municipality. The rate percentage change of mortality due to cancer between both periods was 3% in males and 9% in females. Unlike morbidity, the risk of dying due to cancer was similar between males and females (GRm/w of 1:1). Tables 4 and 5 show the

Table 3. Municipality of Pasto, Colombia. Incidence rates of cancer, crude and age-standardized (world population) per 100.000
person-years in women by location, 1998-2002 and 2003-2007

		1998	2002			2003	2007		APC	: (%)	
Site	n	(%)	CR	ASR	n	(%)	CR	ASR	CR	ASR	Code ICD 10
Oral Cavity and Pharynx	17	1.2	1.9	1.9	21	1.4	2.1	2.1	0.11	0.11	C00 14
Oesophagus	12	0.9	1.3	1.3	13	0.9	1.3	1.2		[0.08]	C15
Stomach	189	13.8	20.9	20.8	161	10.7	16.2	15.7	[0.22]	[0.25]	C16
Small intestine	3	0.2	0.3	0.3	3	0.2	0.3	0.3			C17
Colon and rectum	61	4.5	6.7	6.6	75	5	7.5	7.5	0.12	0.14	C18 20
Anus	5	0.4	0.6	0.6	8	0.5	0.8	0.8	0.33	0.33	C21
Liver	26	1.9	2.9	2.7	32	2.1	3.2	3.2	0.1	0.19	C22
Gallbladder	59	4.3	6.5	6.4	48	3.2	4.8	5.2	[0.26]	[0.19]	C23 24
Pancreas	21	1.5	2.3	2.3	53	3.5	5.3	5.3	1.3	1.3	C25
Nose, sinuses etc	0	0	0	0	3	0.2	0.3	0.3			C30 31
Larynx	0	0	0	0	1	0.1	0.1	0.1			C32
Trachea, bronchus and Lung	24	1.8	2.6	2.5	37	2.5	3.7	3.8	0.42	0.52	C33 34
Other thoracic organs	2	0.1	0.2	0.3	3	0.2	0.3	0.2	0.5		C37 38
Bones	6	0.4	0.7	0.7	7	0.5	0.7	0.6			C40 41
Connective tissue	15	1.1	1.7	1.7	15	1	1.5	1.6	[0.12]		C47,49
Mesothelioma	3	0.2	0.3	0.4	0	0	0	0	[1]		C45
Kaposi sarcoma	0	0.2	0.0	0.1	1	0.1	0.1	0.8	[,]	1.1	C46
Melanoma of skin	31	2.3	3.4	3.3	30	2	3.1	3.2	[0.09]	[0.03]	
Other skin	10	0.7	1.1	1.5	10	0.7	1.4	1.4	0.27	-0.07	
Breast	219	16	24.2	24.3	255	16.9	25.6	26.7	0.06		C50
Vulva	5	0.4	0.6	0.5	5	0.3	0.5	0.6	[0.17]		C51
Vagina	8	0.4	0.0	0.8	0	0.5	0.0	0.0	[0.17]		C52
Uterus unspecified	4	0.3	0.4	0.4	1	0.1	0.1	0.1	[0.75]	-0.75	
Cerv ix uteri	263	19.2	29.1	28.5	271	18	27.2	27.3	-0.07	[0.04]	
Corpus uteri	38	2.8	4.2	4.5	45	3	4.5	4.7	0.07	0.04	
Ovary		2.0 4.4	4.2 6.6	4.J 6.7	43 70	4.6	4.3 7.3	7.8	0.07	0.04	
Placenta	2	4.4 0.1	0.0 0.2	0.2	70	4.0 0.3	7.3 0.4	7.8 0.3	0.11		C58
	10	0.1			13			1.4			
Kidney	10	0.7	1.1 0.1	1.1	0	0.9 0	1.3 0	1.4	0.18	0.27	
Renal pelvis	17			0.6 1.8					[1]		C65
Bladder		1.2	1.9		14	0.9	1.4	1.5	[0.26]	-0.17	
Other urinary organs	0	0	0	0	1	0.1	0.1	0.7	10.051	10.051	C68
Eye	7	0.5	0.8	0.8	6	0.4	0.6	0.6	[0.25]	[0.25]	
Brain, nerv ous system	23	1.7	2.5	2.7	27	1.8	2.7	2.8	0.08		C70 72
Thyroid	71	5.2	7.8	7.8	87	5.8	8.7	8.4	0.12	0.08	
Adrenal gland	1	0.1	0.1	0.2	0	0	0	0	[1]		C74
Hodgkin disease	9	0.7	1	0.9	7	0.5	0.7	0.7	[0.3]	[0.22]	
Non Hodgkin lymphoma	56	4.1	6.2	5.9	62	4.1	6.2	6.3			C82 85,96
Multiple Myeloma	8	0.6	0.9	1	19	1.3	1.9	2.1	1.11		C90
Lymphocytic Leukemia	28	2	3.9	3.4	20	1.3	2.8	2.2	[0.28]	[0.35]	
Myeloid Leukemia	4	0.3	0.4	0.4	9	0.6	0.9	0.9	1.25		C92 94
Leukemia of unspecified cell type	3	0.2	0.3	0.3	5	0.3	0.5	0.5	0.67	0.67	
Myelodysplastic syndromes	0	0	0	0	3	0.2	0.3	0.3			CIE O 3: 998_/3
Unknown primary site	48	3.5	5.3	5.4	62	4.1	6.2	6.2	0.17		C26,39,48,76,80
All sites	1369	100	151.3	150.3	1507	100	151.3	152.4			C00 96
All sites excl. Non melanoma skin cancer	1359	99.3	149.9	149.3	1497	99.3	150.3	151.3	0	0.01	C00 43,45 96

Number cases (n); Relative Frequencies (%); Crude Rate (CR); Age-Standardized Incidence Rate (ASR); Annual Percent Change (APC).

number of deaths and rates of mortality by gender and sites for the study periods. The ratio between incidence rates and mortality was 2:1, for both five-year periods for males and females.

Cancer incidence and mortality according to sites

For both periods evaluated, Figures 2 and 3 present the cancer incidence and mortality of the most frequent tumors in the municipality of Pasto according to gender. In males, the most frequent tumors were: stomach (26%), prostate (17%), lymphomas (7%), lung (5%),

and colorectal (4.6%). In females, a predominance of cervical (19%), breast (16%), stomach (12%), thyroid gland (6%), and colorectal (5%) tumors is noted. The frequency distribution for the most incidental tumors was kept along the decade evaluated.

In males, stomach tumors represent 32% of deaths due to cancer, followed by lung (11%), prostate (7%), liver (6.7%) tumors and lymphomas (6%). In females, the main causes of death due to cancer were: stomach (19%), cervix (13%), breast (11%), pancreas (7%), and lung (6%). In all, these tumors represent 62% of

Table 4. Municipality of Pasto, Colombia. Mortality rates of cancer, crude and age-standardized (world population) per 100,000
person-years in men by location, 1998-2002 and 2003-2007

		1998	-2002		2003-2	007		APC	(%)	
Site	n	(%)	CR	ASR	n	(%)	CR	ASR	CR	ASR Code ICD-10
Mouth and oropharynx	3	0.5	0.4	0.4	4	0.6	0.4	0.4	-	- C00-14
Oesophagu	22	4	2.6	3.2	25	3.9	2.7	3.1	0.04	-0.03 C15
Stomach	190	34.4	22.3	26.6	172	26.5	18.8	21.5	-0.16	-0.19 C16
Colon and rectum	15	2.7	1.8	1.9	34	5.2	3.7	4.2	1.06	1.21 C18-20
liver	28	5.1	3.3	4.3	48	7.4	5.2	6.4	0.58	0.49 C22
Pancreas	20	3.6	2.3	3.1	28	4.3	3.1	3.4	0.35	0.1 C25
Frachea, bronchus and lung	62	11.2	7.3	9.2	61	9.4	6.7	7.3	-0.08	-0.21 C33-34
Aelanoma skin	9	1.6	1.1	1.3	2	0.3	0.2	0.3	-0.82	-0.77 C43-C44
Breast	2	0.4	0.2	0.2	1	0.2	0.1	0.1	-0.5	-0.5 C50
Cervix uteri cancer	-	-	-	-	-	-	-	-	-	- C53
Corpus uteri cancer	-	-	-	-	-	-	-	-	-	- C54
Dvary cancer	-	-	-	-	-	-	-	-	-	- C56
Prostate	66	11.9	7.7	9.4	81	12.5	8.9	9.2	0.16	-0.02 C61
Bladder	9	1.6	1.1	1.4	7	1.1	0.8	0.7	-0.27	-0.5 C67
ymphomas and multiple myeloma	37	6.7	2.9	4.4	45	6.9	2.3	5.7	-0.21	0.3 C81-85+C90+C96
Leukemia	25	4.5	4.3	2.8	21	3.2	4.9	2.4	0.14	-0.14 C91-97
Other sites	65	11.8	7.6	8.8	119	18.4	13	14.6	0.71	0.66
All sites	553	100	64.9	76.9	648	100	70.8	79.4	0.09	0.03 C00-96

Number cases (n); Relative Frequencies (%); Crude Rate (CR); Age-Standardized Incidence Rate (ASR); Annual Percent Change (APC).

the total mortality due to cancer in males and 56% in females. From 2003 to 2007, morbidity and mortality of stomach and cervical cancer diminished, while for the rest of the most frequent tumors in males (prostate, lymphomas, lung, colorectal) and in females (breast, thyroid, colorectal) increased. During the periods evaluated, the incidence of larynx, esophagus, lung, and bladder tumors was higher in males (GRm/w≈2). Anal, thyroid gland, gall bladder, and breast tumors showed higher incidence rates in females.

Cancer incidence and mortality by age groups

In general, cancer incidence rates increased with age, mainly as of 30 years of age. Between 25 and 60 years of age, cancer incidence is higher in females than in males. Mortality rates by age groups are similar in males and females (Fig. 4).

The relative frequency of the different types of cancer had variations according to age and gender. The most frequent tumors among individuals younger than 15 years of age were leukemia and lymphomas that represent approximately 62% of the incidence cases and 52% of the deaths in both genders. In the group 15-49 years of age, stomach cancer was in the first place in males (17%), followed by testicular cancer (14%); in females, the highest proportion occurred with cervical cancer (28%) and breast cancer (18%).


The main causes of mortality in the same age group were stomach tumors (22%) and lymphomas in males (16%); cervical tumors (24%) and breast tumors (15%) in females.


In the group 50-64 years of age, higher incidence of stomach (30%) and prostate (13%) cancer were reported in males; while breast cancer (23%) and cervical cancer (19%) were highest in females. In this age group, the main causes of mortality are stomach tumors (28%) and lung tumors (12%) in males and stomach tumors (17%) and cervical tumors (17%) in females.

As with the previous group, in the group 65 years and older, stomach cancer (28%) and prostate cancer (25%) in males are the most frequent sites, while in females stomach cancer (19%) appeared as the most incidental, displacing cervical cancer (13%) and breast cancer (11%). Stomach tumors in males (36%) and in females (24%) are the main causes of mortality.

Discussion

In the municipality of Pasto, when comparing the estimation of population risk, it was found that the annual mean rate of incidence per every 100,000





person-years increased from 133.4 to 138.1 during the periods evaluated. Increased risk of cancer has been documented in different populations around the world and is explained, in part, by population increase and aging, detriment of life habits, broadened coverage of healthcare services, and technological progress as important factors for the detection of new cancer cases⁷.

Aging is a process quite marked in developed nations; it is principally associated to industrialization and economic modernization. Latin American countries are engaged in "full demographic transition", that is, they present a significant fertility decrease and increased life expectancy, favoring the aging of their populations and the increased proportion of elderly adults, who have higher risks of presenting chronic and degenerative diseases like cancer.

The rate between the elderly population and the young population or aging index (AI) for these countries has increased considerably during the last decades, a phenomenon that is also observed in the municipality of Pasto, which for 1985 reported an AI of 9.1 increasing to 23.1 by 2005; a value higher than that reported for Colombia during the same year (16.5)^{8,9}.

Regarding mortality, in the Municipality deaths due to cancer increased from one period to another, while deaths due to cardiovascular disease – which are the first cause of mortality - diminished.

If this tendency were to remain, in the future cancer could represent the first cause of death in the municipality of Pasto.

The 2:1 incidence/mortality proportion, observed in the Municipality, is common in developing countries and differs from that reported for some populations of developed countries, reaching values of 4:1¹⁰. These contrasts are mainly explained by the differences in: a) the stage of the disease upon diagnosis; b) access to care and treatment, especially in rural populations; c) offer of healthcare services; d) education, life habits, cultural and psychosocial aspects of the population^{11,12}.

Regarding the gender ratio, in the municipality of Pasto the risk of developing cancer is 10% higher in females than in males. In industrialized nations, the risk is higher in males and in developing countries it is higher in females. In Quito (Ecuador), it was observed during the last 20 years that the difference between incidence rates per gender is reduced because of an important

		1998-	2002			2003-2	007		APC ((%)	
Site	n	(%)	CR	ASR	n	(%)	CR	ASR	CR	ASR Code	ICD-10
Mouth and oropharynx	2	0.3	0.2	0.2	3	0.4	0.3	0.3	0.5	0.5 COO-	14
Oesophagus	8	1.3	0.9	1	11	1.6	1.1	1	0.22	- C15	
Stomach	131	21.8	14.5	14.1	121	17.3	12.1	12	-0.17	-0.15 C16	
Colon and rectum	25	4.2	2.8	2.5	41	5.8	4.1	4.1	0.46	0.64 C18-	20
Liver	31	5.2	3.4	3.6	44	6.3	4.4	4.2	0.29	0.17 C22	
Pancreas	36	6	4	4	52	7.4	5.2	5.3	0.3	0.33 C25	
Trachea, bronchus and lung	38	6.3	4.2	4	41	5.8	4.1	4.2	-0.02	0.05 C33-	34
Melanoma skin	13	2.2	1.4	1.4	11	1.6	1.1	1	-0.21	-0.29 C43-	44
Breast	69	11.5	7.6	7.6	73	10.4	7.3	7.6	-0.04	- C50	
Cervix uteri	107	17.8	11.8	11.6	65	9.3	6.5	6.6	-0.45	-0.43 C53	
Corpus uteri	2	0.3	0.2	0.2	14	2	1.4	1.5	6	6.5 C54	
Ovary	0	0	0	0	30	4.3	3	3.2		C56	
Prostate	-	-	-	-	-	-	-	-	-	- C61	
Bladder	7	1.2	0.8	0.8	5	0.7	0.5	0.5	-0.38	-0.38 C67	
Lymphomas and multiple myeloma	34	5.7	3.3	3.8	34	4.9	2.4	3.5	-0.27	-0.08 C81-	85+C90+C96
Leukemia	30	5	3.8	3.3	24	3.4	3.4	2.5	-0.11	-0.24 C91-	97
Other sites	68	11.3	7.5	7.5	132	18.8	13.3	13.6	0.77	0.81	
All sites	601	100	66.3	65.6	701	100	70.4	71.2	0.06	0.09 COO-	96

Table 5. Municipality of Pasto, Colombia. Mortality rates of cancer, crude and age-standardized (world population) per 100,000person-years in women by location, 1998-2002 and 2003-2007

Number cases (n); Relative Frequencies (%); Crude Rate (CR); Age-Standardized Incidence Rate (ASR); Annual Percent Change (APC).

growth of the rates in males, while in females these have remained stable¹³.

The incidence of tumors associated to cigarette smoking and alcoholism (lung, larynx, esophagus, kidney, and urinary bladder) is higher in males, which suggests higher exposure of the male population from the municipality to these risk factors¹⁴. However, the percentage of incidence increase of these tumors during both five-year periods was higher in females. This behavior can be related to changes in the prevalence of cigarette smoking and alcohol consumption in females¹⁵.


When comparing the incidence rates of the most frequent tumors in the municipality of Pasto during the study periods to those reported for other populations in Latin America, like Cali and Quito, during similar periods, it was found that the population from the municipality is at higher risk of developing stomach cancer in both genders and cervical cancer in females. In breast tumors in females and prostate tumors in males, the risk presented in the municipality is lower to that of these populations¹⁶.


The municipality of Pasto and municipalities from the Andean zone in the Department of Nariño are considered high-risk zones for the development of gastric cancer. Studies conducted in these populations contribute to understanding the process of carcinogenesis, which initiates with a prolonged precancerous stage during childhood as a product of *Helicobacter pylori* infection. The subsequent stages include multifocal gland atrophy, intestinal metaplasia, and dysplasia¹⁷.

Other studies aimed the knowledge of the dynamics of the *Helicobacter pylori* in children from zones of high and low risk of cancer in the Department of Nariño show that in the municipality of Pasto, considered high risk, the prevalence of the infection in children one year of age was 34.3%, this percentage increased significantly at six years of age to 80%. A similar pattern was observed in Tumaco, with low risk of gastric cancer, where the prevalence was at 32.3% at one year of age and 67.7% at six years of age.

The prevalence of *Helicobacter pylori* infection and age at which the bacteria were acquired were similar in both populations, which suggests other determinants of the risk of gastric cancer besides infection, i.e., those associated to the bacteria virulence, external environment, the host and other factors like habits and customs of the individuals¹⁸.

In populations at high risk of gastric cancer, via





effective treatment of Helicobacter pylori infection and by complementing the diet with antioxidant micronutrients can interfere in the precancerous process and increase the regression rate of the cancer precursor lesions; this can be an efficient strategy to prevent gastric carcinoma¹⁹. In intervened populations in Europe and the United States diminished incidence and mortality of gastric cancer approaches 50% during monitoring periods over 25 years.


Currently, these populations have the lowest rates of gastric cancer incidence and mortality in the world²⁰. As with gastric cancer, cervical cancer is considered a disease of multifactor origin and it is associated risk factors: behavioral (number of sex partners, use of oral contraceptives, cigarette smoking) and sexually transmitted infections²¹.

The human papillomavirus (HPV) is considered one of the precursors of the cervical carcinogenesis process; studies show that the HPV is found in approximately 97% of the females with these tumors. The HPV is classified into high- and low-risk strains; the highrisk strains increase by 70% the risk of having cervical cancer²².

The WHO and other authors indicate that between 1960 and 2000 cervical cancer prevention programs were successful in populations from developed countries like the USA and Canada, where 60 to 80% reductions were noted in incidence rates and where - currently the figures remain below 10 annual cases per 100,000 females years²³.

In Latin America, the Quito Population-based Cancer Registry reported 21% decrease of cervical cancer mortality and incidence during a 10-year evaluation period through the screening program. In Colombia, Cali Cancer Registry identified the cervical cancer epidemic in Cali; this finding served as the basis to

Figure 4. Municipality of Pasto, Colombia. Incidence and mortality rates for all cancers by sex and age, 1998-2007



establish a vaginal cytology program in the city and documented the drastic decrease of the incidence upon implementing the program²⁴.

In the municipality of Pasto, when analyzing the behavior of cervical cancer during both periods a slight decrease of incidence rates was noted compared to the decrease reported in populations with prevention programs.

The rate percentage change of cancer incidence and mortality in the rest of the most frequent tumors in the municipality is coherent with that reported in other populations. In conclusion, cancer in general constitutes an important health problem for the population from the municipality of Pasto.

The global behavior of incidence and increased mortality due to cancer in relationship to other causes of death evidences the need to sponsor and enhance promotion and prevention programs, especially focused on tumors that produce greater morbidity and mortality in the population.

Acknowledgments

The authors express their gratitude to the work group in the Cancer Registry of Pasto, Universidad de Nariño, Cali Cancer Registry, Pasto's Municipal Secretary of Health, and the National Cancer Institute.

This research was funded by the Center of Health Studies at Universidad de Nariño, Universidad de Nariño, Pasto's Municipal Secretary of Health, and the National Cancer Institute.

Conflict of interest

The authors declare having no conflict of interest with the publication of this article.

References

1. Organización Mundial de la Salud. Cáncer Nota descriptiva Nº 297. Washington: Organización Mundial de la Salud; 2011.

2. Organización Mundial de la Salud, Unión internacional contra el cáncer. Acción Mundial contra el cáncer. OMS, UICC; 2005. p. 24.

3. Piñeros M, Murillo R. Incidencia de cáncer en Colombia: Importancia de las fuentes de información

en la obtención de cifras estimativas. Rev Colomb Cancerol. 2004; 8(1): 5-14.

4. Pardo C, Cendales R. Incidencia estimada y mortalidad por cáncer en Colombia, 2002 -2006. Ministerio de la Protección Social.Instituto Nacional de Cancerología E.S.E. Ministerio de la Protección Social; 2010.

 International Agency for Research on Cancer; World Health Organization; International Association of Cancer Registries; European network of cancer registries. International rules for multiple primary cancers ICDO. Lyon: IARC; WHO; IACR; ENCR 2004.
 Estimaciones y proyecciones de población periodo 1985-2020 [database on the Internet]. DANE. [cited 2011]. Available from: http://www.dane.gov.co.

7. Colombia. Ministerio de la Protección Social. Instituto Nacional de Cancerología, E. S. E. 2011. Guía para el análisis de la situación del cáncer. In Serie documentos técnicos INC No. 4.

8. Latin American and Caribbean Demographic Centre. Proyección de población In: Observatorio demográfico, editor. CELADE; 2009.

9. Ortega Ordoñez, X. A. & F. J. Villamarín (2010) Transición demográfica: una dimensión empírica de la modernización en la zona andina de Nariño. Semestre Económico. 2010, 13(27): 117-36.

10. GLOBOCAN 2008, V1,2 Cancer Incidence and Mortality Worldwide. Cancer Base No. 10 [database on the Internet]. 2008 [cited 2011]. Available from: http:// globocan.iarc.fr.

11. Gwenn M, Anton K. Social inequalities in cancer incidence and cancer survival: Lessons from Danish studies. Eur J Cancer. 2008; 44(14): 1933-7.

12. Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia K, Chen J, *et al.* Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol. 2010; 11(2): 165-73.

13. Cueva P, Yépez C. Epidemiologia del cáncer en quito 2003- 2005. 14 ed. Quito: Sociedad de Lucha contra el Cáncer - SOLCA; 2009. 14. World Health Organization, International Agency for research on cancer. Monographs on the Evaluation of Carcinogenic Risks to Humans. A Review of Human Carcinogens Part B: Biological Agents. Lyon: WHO, IARC; 2009.

15. Wilsnack R, Vogeltanz N, Wilsnack S, Harris T, Ahlström S, Bondy S. Gender differences in alcohol consumption and adverse drinking consequences: cross-cultural patterns. Addiction 2000. 95(2): 251-65.

16. Curado M, Edwars B, Shin H, Storm H, Ferlay J, Heanue M, *et al.* Cancer incidence in five continents, Vol. IX. Lyon: International Agency for Research on Cancer, International Association of Cancer Registries; (Scientific Publications N°160) 2007.

17. Correa P. A New Paradigm for Human Carcinogenesis. J Clin Gastroenterol. 2000; 30(4): 341-2.

18. Camargo M, Yepez M, Ceron C, Guerrero N, Bravo L, Correa P, *et al.* Age at acquisition of *Helicobacter pylori infection*: comparison in two areas with contrasting risk of gastric cancer. Helicobacter. 2004; 9(3): 262-70.

19. Correa P, Fontham E, Bravo J, Bravo L, Ruiz B, Zarama G, *et al.* Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst. 2000; 92(23): 1881-9.

20. Bertuccio B, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, *et al.* Recent patterns in gastric cancer: A global overview. Int J Cancer. 2009; 125(3): 666-73.

21. Stanley M. Human papillomavirus and cervical carcinogenesis. Best Pract Res Clin Obstet Gynaecol. 2001; 15(5): 663-76.

22. Muñoz N, Bosch F, de Sanjosé S, Herrero R, Castellsagué X, Shah K, *et al.* Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348(6): 518-27.

23. Lewis M. Análisis de la situación del cáncer cervicouterino en América Latina y el Caribe. Washington, DC: OPS. 2004.

24. Organización Mundial de la Salud, Organización Panamericana de la Salud. Registros de cáncer Información para la acción en América Latina y el Caribe. Lyon OMS-OPS 2012.